President Trump Ordered Research into Psychedelic Drugs
The executive order aims to accelerate federal research into new treatments for mental health conditions.
Updated on Oct. 14, 2026 in Substance Abuse
Live Poll
Should federal research prioritize the development of psychedelic drugs for treating severe mental health conditions?
President Donald Trump has signed an executive order to accelerate federal research on the use of psychedelic drugs for mental health. As part of this push, the FDA is currently fast-tracking the review of three different psychedelic therapies for conditions like depression and PTSD.
Why it matters
This executive action aims to potentially broaden clinical treatment options for mental health conditions by fast-tracking the rigorous evaluation of substances that remain illegal at the federal level. The focus is to translate emerging data into accessible, FDA-regulated medical therapies.
The FDA is currently evaluating three psychedelic drugs for potential approval. While ketamine is the only legal psychedelic medicine currently used in North Carolina, future approvals for other compounds could occur later this year.
The players
President Donald Trump
The current President of the United States who signed the executive order to accelerate federal research on psychedelic medicine.
FDA
The federal agency responsible for evaluating the safety and efficacy of new drug therapies before they reach the public.
The details
Ketamine is currently administered in clinical settings through an IV over the course of one-hour sessions, with transformations often reported over six weeks. While researchers study various compounds, they note that substances like ibogaine involve an intense, single all-day session and present more significant heart-related risks than ketamine. These administrative efforts aim to standardize the delivery of these therapies through medical supervision.
Timeline
October 14, 2026: President Donald Trump signed the executive order.
Later this year: FDA approvals for psychedelic drugs could occur.
Health Landscape
This move marks a significant departure from the established restrictions of the Controlled Substances Act by prioritizing a clinical pathway for substances previously kept out of the medical mainstream. It follows a growing pattern of state-level legalization in places like Oregon and Colorado.
As federal and state regulations evolve, it is essential to discuss any interest in alternative mental health treatments with your primary care physician. Be aware that most psychedelic therapies remain legally restricted and that safety risks, particularly regarding cardiac health, vary significantly by substance.
The takeaway
The federal push for research underscores a shift toward integrating psychedelic medicine into regulated mental health care. Discuss your current treatment plan with your physician before considering any emerging therapeutic options for depression or PTSD.
Further reading
Learn more about the evolving clinical landscape for mental health care in the Substance Abuse section.
Live Poll
Should federal research prioritize the development of psychedelic drugs for treating severe mental health conditions?
